<DOC>
	<DOCNO>NCT02195323</DOCNO>
	<brief_summary>This study design provide confirmation safety mesenchymal stem cell ( MSCs ) therapy chronic kidney disease ( CKD ) .</brief_summary>
	<brief_title>Autologous Bone Marrow Derived Mesenchymal Stromal Cells ( BM-MSCs ) Patients With Chronic Kidney Disease ( CKD )</brief_title>
	<detailed_description>We assess 18-month safety potential efficacy autologous MSCs therapy CKD . A total 10 patient CKD IV injection high dose 2Ã—106/kg autologous MSCs , derive biopsy bone marrow . Assessments perform 1 , 3 , 6 , 12 18 month cell injection . Changes Glomerular Filtration Rate ( GFR ) evaluate scan isotope .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Male Female CKD symptom CKD confirm serum urine analysis GFR 2560 mL/min/1.73 m2 Patient 's age 25 60 year Ability understand willingness sign consent Pregnant lactate Basis disease diabetes , malignancy autoimmune Unable follow postoperative exercise regimen return evaluation</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>autologous bone marrow mesenchymal stem cell chronic kidney disease</keyword>
</DOC>